Get the Stockscreener App
3.97
7.59%
0.28
After Hours:
4.00
0.03
+0.76%
Akebia Therapeutics Inc stock is traded at $3.97, with a volume of 8.17M.
It is up +7.59% in the last 24 hours and up +71.12% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$3.69
Open:
$3.66
24h Volume:
8.17M
Relative Volume:
1.57
Market Cap:
$795.79M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-14.18
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+31.02%
1M Performance:
+71.12%
6M Performance:
+93.66%
1Y Performance:
+271.03%
1-Day Range:
$3.66
$4.00
1-Week Range:
$2.97
$4.00
52-Week Range:
$0.80
$4.00
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.97 | 795.79M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
170.16 | 75.08B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
11.07 | 51.07B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 46.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.77 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
325.82 | 14.38B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa
Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha
Akebia reports mixed results for anemia drug in global study - Investing.com
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus
Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA Stock News - GuruFocus
Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com
Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vafseo | AKBA Stock News - GuruFocus
Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa
Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AKBA Stock News - GuruFocus
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire
Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan
Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire
Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India
Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada
Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia
Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus
Raymond James Financial Inc. Invests $85,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mariner LLC Invests $28,000 in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by MetLife Investment Management LLC - Defense World
Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Sets New 52-Week High After Strong Earnings - Defense World
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: - GuruFocus
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus
Stock Traders Purchase Large Volume of Akebia Therapeutics Call Options (NASDAQ:AKBA) - Defense World
Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):